Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma
Abstract Studies comparing the efficacy and safety of R-CHOP and modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-90 (NHL-BFM-90) regimens in children and adolescents with diffuse large B-cell lymphoma (DLBCL) are lacking. Thus, we retrospectively analyzed 85 DLBCL patients aged ≤18 years from 2000 to 2020; 74 patients received the modified NHL-BFM-90 regimen, and 11 received the R-CHOP regimen. The 5-year OS and event-free survival (EFS) rates between the modified NHL-BFM-90 and R-CHOP regimens were 91.0% vs. 90.9% (P = 0.466) and 89.8% vs. 68.6% (P = 0.055), respectively. In the stratified analysis, the survival outcome of pediatric patients treated with the modified NHL-BFM-90 regimen was not significantly different from that of adolescent patients. The OS and EFS rates of patients with early-stage disease were both 100%. Patients in the advanced-stage group who were treated with the modified NHL-BFM-90 regimen had superior EFS rates (P < 0.05). The frequency of severe adverse events from the two regimens was similar. There were no treatment-related deaths. We concluded that the modified NHL-BFM-90 regimen has better efficacy than R-CHOP in DLBCL patients with advanced-stage disease. However, the R-CHOP regimen might be an option for early-stage DLBCL. Further prospective studies are needed to guide clinical decisions about treatment..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Annals of hematology - 101(2022), 4 vom: 08. Jan., Seite 763-771 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guan, Jinqiu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Adolescent |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00277-022-04754-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078219975 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078219975 | ||
| 003 | DE-627 | ||
| 005 | 20230516094130.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-022-04754-6 |2 doi | |
| 035 | |a (DE-627)OLC2078219975 | ||
| 035 | |a (DE-He213)s00277-022-04754-6-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Guan, Jinqiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Abstract Studies comparing the efficacy and safety of R-CHOP and modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-90 (NHL-BFM-90) regimens in children and adolescents with diffuse large B-cell lymphoma (DLBCL) are lacking. Thus, we retrospectively analyzed 85 DLBCL patients aged ≤18 years from 2000 to 2020; 74 patients received the modified NHL-BFM-90 regimen, and 11 received the R-CHOP regimen. The 5-year OS and event-free survival (EFS) rates between the modified NHL-BFM-90 and R-CHOP regimens were 91.0% vs. 90.9% (P = 0.466) and 89.8% vs. 68.6% (P = 0.055), respectively. In the stratified analysis, the survival outcome of pediatric patients treated with the modified NHL-BFM-90 regimen was not significantly different from that of adolescent patients. The OS and EFS rates of patients with early-stage disease were both 100%. Patients in the advanced-stage group who were treated with the modified NHL-BFM-90 regimen had superior EFS rates (P < 0.05). The frequency of severe adverse events from the two regimens was similar. There were no treatment-related deaths. We concluded that the modified NHL-BFM-90 regimen has better efficacy than R-CHOP in DLBCL patients with advanced-stage disease. However, the R-CHOP regimen might be an option for early-stage DLBCL. Further prospective studies are needed to guide clinical decisions about treatment. | ||
| 650 | 4 | |a Diffuse large B-cell lymphoma | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Modified NHL-BFM-90 | |
| 650 | 4 | |a R-CHOP | |
| 700 | 1 | |a Sun, Feifei |4 aut | |
| 700 | 1 | |a Wang, Juan |4 aut | |
| 700 | 1 | |a Huang, Junting |4 aut | |
| 700 | 1 | |a Lu, Suying |4 aut | |
| 700 | 1 | |a Zhu, Jia |4 aut | |
| 700 | 1 | |a Zhu, Xiaoqin |4 aut | |
| 700 | 1 | |a Huang, Huiqiang |4 aut | |
| 700 | 1 | |a Xia, Zhongjun |4 aut | |
| 700 | 1 | |a Que, Yi |4 aut | |
| 700 | 1 | |a Cai, Ruiqing |4 aut | |
| 700 | 1 | |a Zhen, Zijun |4 aut | |
| 700 | 1 | |a Sun, Xiaofei |4 aut | |
| 700 | 1 | |a Zhang, Yizhuo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Springer Berlin Heidelberg, 1991 |g 101(2022), 4 vom: 08. Jan., Seite 763-771 |w (DE-627)130956759 |w (DE-600)1064950-5 |w (DE-576)025101188 |x 0939-5555 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2022 |g number:4 |g day:08 |g month:01 |g pages:763-771 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00277-022-04754-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2022 |e 4 |b 08 |c 01 |h 763-771 | ||